Training and Knowledge-sharing Workshop: Applying non-animal strategies for assessing skin sensitisation

A joint EPAA / Cefic-LRI / IFRA Europe workshop

7-8 February 2019, ECHA offices, Helsinki, Finland

PROGRAMME

Day 1

12:15-13:15	**Networking Welcome Lunch**
13:15-13:30	Workshop Introduction and expected outcome(s) (*David Basketter, WS Moderator*)
13:30-13:45	Setting the scene: update from EURL ECVAM and OECD activities (*Silvia Casati, DG JRC*)
13:45-14:00	ECHA's experience on the use of non-animal data for skin sensitisation (*Laura Rossi, ECHA*)
14:00-14:15	Experience from the Chemical sector (*Robert Landsiedel, BASF/Cefic*)
14:15-14:30	Experience from the Agrochemical sector (*Marco Corvaro, Dow/ECPA*)
14:30-14:45	Fragrance sector experience with *in vitro* test battery in REACH (*Peter Griem, Symrise/IFRA Europe*)
14:45-15:15	**Coffee break**
15:15-15:30	Experience from the *Silicone sector* (*Dorothea Eigler, Evonik/CES*)
15:30-15:45	Cosmetic Ingredient suppliers' experience (*Reinhard Kreiling, EFfCI*)
15:45-16:00	Experience from the Cosmetic sector (*Petra Kern, P&G/Cosmetics Europe*)
16:00-16:15	SCCS experience and expectations on alternatives to animal testing (*Janine Ezendam, SCCS*)
16:15-16:30	Update from the IDEA project (predicting potency of skin allergens without animal testing), (*Prof. Jim Bridges, Chair of IDEA Supervisory Group*)
16:30-16:45	Results of the EPAA "Difficult to test substances" project (*Annette Mehling, BASF*)
16:45-17:00	Wrap-up and closing of Day 1 (*David Basketter*)
19:00-21:00	**Dinner**

Attendance upon invitation

Day 2

08:15-08:30 Brief summary of previous day as introduction to the Break-out groups (*David Basketter*)

08:30-10:00 **Break-out groups** (90 minutes)

1. **BOG 1**: *Using case studies, how to select the best portfolio of methods from the plethora of non-animal tests that are now available*

Q1: There is a feeling that perhaps only two methods are the most effective route to hazard identification; does adding more assays only increase uncertainty?
Q2: In the past, approaches regarded as a "black box" were not favoured; might this bias be changing?

2. **BOG 2**: *Consider the challenges presented by substances which deliver discordant/hard to interpret results*

Q1: Is the only way to deal with discordant results to undertake more testing?
Q2: Should we be doing more to understand the chemistry of skin sensitisation and use this as the basis for dealing with difficult outcomes?

3. **BOG 3**: *Detail progress on potency estimation for regulatory sub-categorisation and risk assessment*

Q1: Do we now have combined approaches which deliver sub-categorisation with at least as much accuracy as the LLNA?
Q2: Is there any possibility that further adaptation of these approaches will deliver complete potency assessment of the type required for QRA?

10:00-10:30 Coffee break

10:30-11:00 Break-out group presentations (10 minutes per group)

11:00-12:00 Plenary discussion and agreed recommendations

12:00-12:30 Round-up and Conclusions (*David Basketter*)

12:30-13:30 Networking Lunch